pENTR-N90-beta-catenin Citations (3)

Originally described in: Distinct pathways of genomic progression to benign and malignant tumors of the liver.
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6. Epub 2007 Sep 4. PubMed Journal

---

Articles Citing pENTR-N90-beta-catenin

Articles
C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis. Han R, Hu S, Qin W, Shi J, Hou Q, Wang X, Xu X, Zhang M, Zeng C, Liu Z, Bao H. JCI Insight. 2019 Apr 4;4(7). pii: 122912. doi: 10.1172/jci.insight.122912. eCollection 2019 Apr 4. PubMed
The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma. Berger AA, Kawaler EA, Dao F, Misirlioglu S, Fernandez EA, Olvera N, Van Oudenhove E, DeLair D, Levine DA. Gynecol Oncol. 2022 Sep 20:S0090-8258(22)01827-3. doi: 10.1016/j.ygyno.2022.09.013. PubMed
Proteomes from AMPK-inhibited peripheral blood mononuclear cells suppress the progression of breast cancer and bone metastasis. Li K, Sun X, Minami K, Tamari K, Ogawa K, Li H, Ma H, Zhou M, Na S, Li BY, Yokota H. Theranostics. 2023 Feb 5;13(4):1247-1263. doi: 10.7150/thno.80294. eCollection 2023. PubMed

If you have published an article using this material, please email us at to have your article added to this page.